Press Releases

    Print Page  Close Window
BioMed Realty Trust Reports Third Quarter 2007 Financial Results

SAN DIEGO, Nov. 7 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR), a real estate investment trust focused on providing real estate to the life science industry, today announced financial results for the third quarter ended September 30, 2007.

    Highlights:

    -- Funds from operations (FFO) for the quarter were $30.8 million, or
       $0.45 per diluted share

    -- Net income available to common stockholders increased 13% to
       $12.2 million versus the third quarter of 2006

    -- Total assets of $3.0 billion at quarter end represented a 40.6%
       increase from September 30, 2006

    -- Executed 16 leasing transactions representing greater than 290,000
       square feet, bringing the year-to-date total gross leasing transaction
       volume to 741,000 square feet:

         -- Thirteen new leases totaling approximately 146,000 square feet,
            bringing the year-to-date 2007 total for new leases to
            approximately 288,000 square feet, and

         -- Three leases amended to extend their terms and totaling
            approximately 144,000 square feet, bringing the year-to-date 2007
            total for amendments, extensions and renewals to approximately
            453,000 square feet

    -- Increased the occupancy rate of our operating portfolio to 93.3%

    -- Commenced construction on an approximately 280,000 square foot Class A
       laboratory/office facility in East Cambridge, Massachusetts, owned by
       our joint venture with Prudential Real Estate Investors

    -- Closed on the acquisition of two properties located in our core markets
       for total consideration of $49.0 million, bringing the 2007
       year-to-date total acquisitions to $653.8 million:

         -- 238,000 square feet of industrial/warehouse space located in South
            San Francisco, California, which is currently fully leased and
            targeted for future redevelopment as laboratory/office space

         -- 67,000 square feet of laboratory/office space located in San
            Diego, California, which is fully leased to Artes Medical, Inc.

    -- Disposed of two non-core assets, previously held for sale and owned by
       our joint venture with Prudential Real Estate Investors

    -- Amended our $250 million secured term loan, extending the term to
       August 2012, lowering the borrowing rate by 60 basis points, and, when
       combined with our in-place interest rate swap, fixing the effective
       interest rate at 5.8% into 2010

    -- Amended our unsecured line of credit, increasing the available
       borrowings to $600 million, reducing the borrowing rate, extending the
       term to August 2011 and increasing the accordion feature to
       $1.0 billion

"We are very pleased to once again report a strong quarter of financial performance. Our leasing team continues to execute across our core markets, including leasing activity in San Diego, San Francisco, Seattle, Pennsylvania and New York. We remain optimistic as we see continued strength in the life science industry and improving occupancy rates in our core markets," commented Alan D. Gold, President and Chief Executive Officer of BioMed Realty Trust.

"Our development and redevelopment programs continue to make strong progress, and we are excited to have now commenced construction on the new 280,000 square foot Class A laboratory and office facility in East Cambridge that we own with our partner Prudential Real Estate Investors," added Mr. Gold.

Third Quarter 2007 Financial Results

Total revenues for the quarter increased to $64.8 million from $63.8 million in the third quarter of 2006, due primarily to the addition of properties through acquisitions, partially offset by a reduction in revenues from properties generating revenues in 2006 which are currently undergoing redevelopment. Net income available to common stockholders for the quarter was $12.2 million, or $0.19 per diluted share, compared to $10.8 million, or $0.18 per diluted share, in the third quarter of 2006.

FFO during the quarter increased 2.7% to $30.8 million from $30.0 million in the comparable period in 2006. FFO per diluted share was $0.45 for the third quarter of 2007 versus $0.47 in the third quarter of 2006.

FFO is a supplemental non-GAAP financial measure used in the real estate industry to measure and compare the operating performance of real estate companies. A complete reconciliation containing adjustments from GAAP net income available to common stockholders to FFO and a definition of FFO are included at the end of this release.

Financing Activity

On August 1, 2007, the company amended its $250 million secured term loan facility and $500 million unsecured revolving line of credit, reducing the borrowing rates under the facilities and increasing the available borrowings under the revolving facility from $500 million to $600 million. The borrowing rate under the secured term loan was reduced by 60 basis points, which, when combined with the interest rate swap agreement previously entered into by the company, provides an effective interest rate of 5.81% for the facility until the swap expires in 2010. The amendment also extends the term of the secured facility to August 1, 2012 and provides greater flexibility with respect to covenants.

In addition to increasing the available borrowings to $600 million, the amendment to the unsecured line of credit extends the term to August 1, 2011, reduces the borrowing rate and provides greater flexibility with respect to covenants. BioMed may extend the maturity date of the revolving credit facility to August 1, 2012 and may increase the amount of the facility to $1.0 billion upon satisfying certain conditions.

During the third quarter, the company also entered into four new interest rate swaps that have the effect of fixing the LIBOR portions of interest rates on $535 million of its variable rate debt. Two of the interest rate swaps with an aggregate notional amount of $150 million fix LIBOR at 4.68% through August 2011. The remaining two interest rate swaps with an aggregate notional amount of $385 million fix LIBOR at 4.82% through September 2008.

As of September 30, 2007, the company's consolidated debt included fixed-rate mortgage indebtedness with an aggregate outstanding principal amount of $385.8 million, excluding $11.5 million of debt premium, and a weighted-average effective interest rate of 5.43% at quarter-end; the $250 million secured term loan; $175 million aggregate principal amount of 4.50% exchangeable senior notes due 2026; $216.8 million in outstanding borrowings under the company's $600 million unsecured revolving line of credit, with a weighted-average effective interest rate of 6.72% at quarter-end; and $389.9 million in outstanding borrowings under the company's $550 million acquisition and construction loan secured by the Center for Life Science | Boston property, with a weighted-average effective interest rate of 6.38% at quarter-end. The company's debt to total capitalization ratio was 43.1% at September 30, 2007.

"Our strong financial results for the quarter continue to strengthen our credit profile. We are pleased to celebrate another series of successful financing transactions, which were completed in a very difficult global credit market environment, and we appreciate the continued support of our lenders," commented Kent Griffin, Chief Financial Officer of BioMed Realty Trust. "We are fortunate to have a strong liquidity position, with ample capital capacity to continue to execute our business plan, particularly the funding of our development and redevelopment pipeline. In addition, through the use of interest rate swaps that have the effect of fixing interest rates at historically favorable levels, we have significantly mitigated our near-to-medium term exposure to interest rate risk."

    Portfolio Update

    During the quarter, the company acquired the following two properties:

    -- Pacific Center Boulevard -- two office/laboratory buildings comprising
       approximately 67,000 square feet in the Sorrento Valley submarket of
       San Diego, California that are now fully leased to Artes Medical, Inc.

    -- Forbes Boulevard -- one building comprising approximately 238,000
       square feet in the South San Francisco submarket of San Francisco,
       California that is fully leased and targeted for future redevelopment
       as laboratory/office space

The company, through its joint venture with Prudential Real Estate Investors, disposed of certain non-core assets during the quarter, including 25,000 square feet of retail space and additional developable pad sites in Cambridge, Massachusetts and a laboratory/office building and surrounding land parcels in New Haven, Connecticut.

As of September 30, 2007, BioMed Realty Trust owned or had interests in 103 buildings, located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey. The company's portfolio was comprised of the following, with its operating portfolio 93.3% leased to 111 tenants, as of September 30, 2007:



                                                                   Rentable
                                                                  Square Feet
    Operating portfolio                                            6,626,723
    Repositioning and redevelopment properties                     1,871,353
    Construction in progress                                       1,941,000
    Land parcels                                                   1,293,000
      Total proforma portfolio                                    11,732,076


    Quarterly Distributions

BioMed Realty Trust's board of directors previously declared a third quarter 2007 dividend of $0.31 per share of common stock, and a dividend of $0.46094 per share of the company's 7.375% Series A Cumulative Redeemable Preferred Stock for the period from July 16, 2007 through October 15, 2007.

Earnings Guidance

Based on results for the first nine months of 2007, the company has increased earnings guidance for the year ending December 31, 2007. The company's revised 2007 guidance for net income per diluted share and FFO per diluted share is set forth and reconciled below.



                                                                      2007
                                                                  (Low - High)
    Projected net income per diluted share available to
     common stockholders                                          $0.79 - 0.81
        Add:
      Minority interest                                               $0.04
      Real estate depreciation and amortization                       $1.06
      Projected FFO per diluted share                             $1.89 - 1.91

The results for the first nine months of 2007 include approximately $7.7 million, or $0.11 per diluted share, of lease termination income earned in the first and second quarters of 2007.

The company's initial 2008 guidance for net income per diluted share and FFO per diluted share is set forth and reconciled below.



                                                                      2008
                                                                  (Low - High)
    Projected net income per diluted share available to
     common stockholders                                          $0.67 - 0.77
        Add:
      Minority interest                                               $0.03
      Real estate depreciation and amortization                       $1.16
      Projected FFO per diluted share                             $1.86 - 1.96

Consistent with the 2007 guidance, the company's 2008 guidance does not include the impact of future acquisition activities. In addition, the company's 2008 guidance does not include any expected lease termination income.

The foregoing estimates are forward-looking and reflect management's view of current and future market conditions, including certain assumptions with respect to leasing activity, rental rates, occupancy levels, interest rates, and the amount and timing of development and redevelopment activities. The company's actual results may differ materially from these estimates.

Supplemental Information

Supplemental operating and financial data are available in the Investor Relations section of the company's web site at http://www.biomedrealty.com.

Teleconference and Web Cast

BioMed Realty Trust will conduct a conference call and audio web cast at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) Thursday, November 8, 2007 to discuss the company's financial results and operations for the quarter. The call will be open to all interested investors either through a live audio web cast at the Investor Relations section of the company's web site at http://www.biomedrealty.com and http://www.earnings.com, or live by calling (866) 770-7125 (domestic) or (617) 213-8066 (international) with call ID number 10729297. The call will be archived for 30 days on both web sites. A telephone playback of the conference call will also be available from 3:00 p.m. Pacific Time on Thursday, November 8, 2007 through midnight Pacific Time on Tuesday, November 13, 2007 by calling (888) 286-8010 (domestic) or (617) 801-6888 (international) and using access code 99167797.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 68 properties, representing 103 buildings with approximately 8.5 million rentable square feet, as well as approximately 1.9 million square feet of development in progress. These properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at http://www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



                          BIOMED REALTY TRUST, INC.
                         CONSOLIDATED BALANCE SHEETS
               (In thousands, except share and per share data)

                                                   September 30,  December 31,
                                                       2007          2006
                                                   (Unaudited)
                        ASSETS
    Investments in real estate, net                 $2,742,603    $2,457,538
    Investment in unconsolidated partnerships           21,741         2,436
    Cash and cash equivalents                           18,424        25,664
    Restricted cash                                     10,003         6,426
    Accounts receivable                                  3,722         5,985
    Accrued straight-line rents, net                    32,012        20,446
    Acquired above-market leases, net                    6,339         7,551
    Deferred leasing costs, net                        119,699       129,322
    Deferred loan costs, net                            17,052        17,608
    Prepaid expenses                                     4,608         3,627
    Other assets                                        31,959        16,039
        Total assets                                $3,008,162    $2,692,642

          LIABILITIES AND STOCKHOLDERS' EQUITY
    Mortgage notes payable, net                       $397,341      $403,836
    Secured construction loan                          389,904       286,355
    Secured term loan                                  250,000       250,000
    Exchangeable senior notes                          175,000       175,000
    Unsecured line of credit                           216,847       228,165
    Security deposits                                    7,513         7,704
    Dividends and distributions payable                 25,557        19,847
    Accounts payable, accrued expenses, and other
     liabilities                                        81,195        62,602
    Acquired below-market leases, net                   25,220        25,101
      Total liabilities                              1,568,577     1,458,610
    Minority interests                                  19,269        19,319
    Stockholders' equity:
    Preferred stock, $.01 par value, 15,000,000
     shares authorized: 7.375% Series A cumulative
     redeemable preferred stock, $230,000,000
     liquidation preference ($25.00 per share),
     9,200,000 shares issued and outstanding at
     September 30, 2007                                222,413             -
    Common stock, $.01 par value, 100,000,000
     shares authorized, 65,465,839 and 65,425,598
     shares issued and outstanding at September
     30, 2007 and December 31, 2006, respectively          655           654
    Additional paid-in capital                       1,275,347     1,272,243
    Accumulated other comprehensive income               6,945         8,417
    Dividends in excess of earnings                    (85,044)      (66,601)
      Total stockholders' equity                     1,420,316     1,214,713
        Total liabilities and stockholders' equity  $3,008,162    $2,692,642



                          BIOMED REALTY TRUST, INC.
                      CONSOLIDATED STATEMENTS OF INCOME
               (In thousands, except share and per share data)
                                 (Unaudited)

                                    For the Three Months   For the Nine Months
                                     Ended September 30,   Ended September 30,
                                       2007       2006       2007       2006
    Revenues:
        Rental                       $49,382    $49,197   $146,351   $115,808
        Tenant recoveries             15,084     14,632     47,264     39,870
        Other income                     366          9      8,445         79
          Total revenues              64,832     63,838    202,060    155,757
    Expenses:
        Rental operations             12,789     11,030     38,784     30,030
        Real estate taxes              5,079      5,682     16,538     14,409
        Depreciation and amortization 17,665     18,481     54,556     46,283
        General and administrative     5,283      4,609     15,990     13,162
          Total expenses              40,816     39,802    125,868    103,884
          Income from operations      24,016     24,036     76,192     51,873
        Equity in net (loss)/income
         of unconsolidated
         partnerships                   (261)        20       (694)        62
        Interest income                  239        218        809        813
        Interest expense              (7,043)   (13,346)   (21,013)   (30,383)
            Income from continuing
             operations before
             minority interests       16,951     10,928     55,294     22,365
        Minority interests in
         continuing operations of
         consolidated partnerships        51         15        (61)       115
        Minority interests in continuing
         operations of operating
         partnership                    (545)      (497)    (1,821)    (1,131)
            Income from continuing
             operations               16,457     10,446     53,412     21,349
        Income from discontinued
         operations before gain on sale
         of assets and minority interests  -        383        639      1,156
        (Loss)/gain on sale of real
         estate assets                    (1)         -      1,087          -
        Minority interests attributable
         to discontinued operations        -        (17)       (74)       (61)
            (Loss)/income from
             discontinued operations      (1)       366      1,652      1,095
            Net income                16,456     10,812     55,064     22,444
        Preferred stock dividends     (4,241)         -    (12,628)         -
            Net income available to
             common stockholders     $12,215    $10,812    $42,436    $22,444
    Income from continuing operations
     per share available to common
     stockholders:
      Basic and diluted earnings per
       share                           $0.19      $0.17      $0.62      $0.40
    Net income per share available to
     common stockholders:
      Basic and diluted earnings per
       share                           $0.19      $0.18      $0.65      $0.42
    Weighted-average common shares
     outstanding:
      Basic                       65,308,702 60,477,672 65,300,802 52,822,498
      Diluted                     68,274,908 63,646,647 68,262,086 55,926,343



                          BIOMED REALTY TRUST, INC.
     FUNDS FROM OPERATIONS(In thousands, except share and per share data)
                                 (Unaudited)

    The following table provides the calculation of our FFO and a
reconciliation to net income available to common stockholders (in thousands,
except per share amounts):

                                     For the Three Months  For the Nine Months
                                      Ended September 30,  Ended September 30,
                                        2007       2006       2007       2006
    Net income available to common
     stockholders                     $12,215    $10,812    $42,436    $22,444
    Adjustments:
      Minority interests in operating
       partnership                        545        514      1,895      1,192
      Loss/(gain) on sale of real estate
       assets                               1          -     (1,087)         -
      Depreciation and amortization -
       real estate assets
       (unconsolidated partnerships)      366         20        745         60
      Depreciation and amortization -
       real estate assets (consolidated
       entities-discontinued operations)    -        137        228        411
      Depreciation and amortization -
       real estate assets (consolidated
       entities-continuing operations) 17,665     18,481     54,556     46,283
    Funds from operations             $30,792    $29,964    $98,773    $70,390
    Funds from operations per share -
     diluted                            $0.45      $0.47      $1.45      $1.26
    Weighted-average common shares
     outstanding - diluted         68,274,908 63,646,647 68,262,086 55,926,343

We present funds from operations, or FFO, because we consider it an important supplemental measure of our operating performance and believe it is frequently used by securities analysts, investors and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results. FFO is intended to exclude GAAP historical cost depreciation and amortization of real estate and related assets, which assumes that the value of real estate assets diminishes ratably over time. Historically, however, real estate values have risen or fallen with market conditions. Because FFO excludes depreciation and amortization unique to real estate, gains and losses from property dispositions and extraordinary items, it provides an operating performance measure that, when compared year over year, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from net income. We compute FFO in accordance with standards established by the Board of Governors of the National Association of Real Estate Investment Trusts, or NAREIT, in its March 1995 White Paper (as amended in November 1999 and April 2002). As defined by NAREIT, FFO represents net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus real estate related depreciation and amortization (excluding amortization of loan origination costs) and after adjustments for unconsolidated partnerships and joint ventures. Our computation may differ from the methodology for calculating FFO utilized by other equity REITs and, accordingly, may not be comparable to such other REITs. Further, FFO does not represent amounts available for management's discretionary use because of needed capital replacement or expansion, debt service obligations, or other commitments and uncertainties. FFO should not be considered as an alternative to net income (loss) (computed in accordance with GAAP) as an indicator of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity, nor is it indicative of funds available to fund our cash needs, including our ability to pay dividends or make distributions.

SOURCE BioMed Realty Trust, Inc.

CONTACT: Kent Griffin, Chief Financial Officer of BioMed Realty Trust, Inc., +1-858-485-9840

Web site: http://www.biomedrealty.com